The coronavirus pandemic has prompted questions about reinfection and the risk of developing "long Covid" characterized by fatigue, brain fog, musculoskeletal pain, shortness of breath, gastrointestinal disorders, and dysautonomia, among other issues. Research led by Ziyad Al-Aly, chief of research […]
Cognitive Ability Tied to COVID-19 Vaccination Rates
The study published in the Journal of Health Economics investigated a link between an individual's cognitive ability and their decision to receive the COVID-19 vaccination. The researchers found that people with higher cognitive abilities were likely to get vaccinated faster than those with lower […]
Updates to Keep an Eye on
The FDA has fast-tracked approval of Pfizer's Elfrexfio drug for hard-to-treat multiple myeloma, offering new hope to patients. State and local governments are currently wrestling with how best to distribute funding from opioid crisis-related settlements as public health groups question the […]
Act4Biosimilars Advocacy Group Strives to Boost Global Adoption of Biosimilars by 2030
Act4Biosimilars, a global biosimilar advocacy initiative, aims to increase global adoption of biosimilars by at least 30 percentage points in over 30 countries by 2030. Here's what you need to know: Regulatory and policy hurdles and varied market dynamics cause disparities in biosimilar […]
Millennials and Gen Z More Likely to Buy from Brands Promoting Healthy Lifestyle
According to a DirecTV Advertising report, Millennials and Gen Z are more inclined towards brands promoting a healthy lifestyle than Baby Boomers. Approximately 60% of Millennials would likely buy from these brands, compared to 50% of Gen Xers, 39% of Gen Zers, and 38% of Boomers. Over 40% of […]
Infectious Disease Market Projected to Grow by 5.7% Led by Pfizer, Gilead Sciences, and GSK
According to a report by GlobalData, the infectious disease market is projected to grow actively from 2023 to 2029 and sales are predicted to reach $150 billion by 2029. It is expected that Pfizer, Gilead Sciences, and GlaxoSmithKline (GSK) will be the major players in the market. What You Need […]
Groundbreaking Alliance: RetinAI Medical AG Joins Forces with Retina Consultants of America!
RetinAI Medical AG (RetinAI) and Retina Consultants of America (RCA) are partnering to advance artificial intelligence (AI) applications in the analysis of clinical and imaging data in ophthalmology. The partnership leverages RetinAI's digital health technologies and RCA's large patient data network […]
Medlinker’s AI Doctors Almost Match Human Physicians in Groundbreaking Live Test
Medlinker, a Chinese digital healthcare company, hosted a live comparison of its AI doctors, MedGPT, and human doctors in Chengdu, with MedGPT scoring 7.2 out of 10, compared to an average of 7.5 for human doctors, based on an assessment by seven notable physicians. Furthermore, the recommendations […]
ITIF Report: Global Drug Price Controls Restrict Pharmaceutical Research and Development
The Information Technology and Innovation Foundation (ITIF) study reports that drug price controls in non-US Organization for Economic Cooperation and Development (OECD) nations inhibit biopharmaceutical R&D by over $56 billion annually, foregoing the creation of around 25 new drugs yearly. If […]
BridgeBio’s Experimental Results Boosts Company Shares by 65%
BridgeBio Pharma Inc's experimental drug, acoramidis, for rare heart disease, has shown significant improvement in a late-stage study, boosting its market shares by 65%. Acoramidis functions to prevent heart failure by addressing anomalous protein deposits in the heart. It is expected to compete […]
Insights into the Global Real World Evidence Solutions Market 2023-2030
10 Things You Need to Know: The projection shows the market size growing from $16.3 billion in 2023 to $36.24 billion in 2030, with a CAGR of 12.3%. IQVIA Inc., UnitedHealth Group, IBM, and Cognizant are currently the major players to pay attention to in the market. Advanced analytics […]
Price Break: Cigna Welcomes Trio of Discounted Biosimilars to Preferred Drug Roster
What You Need to Know: Cigna Group's unit, Express Scripts, is adding three biosimilar versions of AbbVie's arthritis treatment Humira to its preferred drugs list. Reuters explains that “The biosimilars include Hyrimoz and an unbranded version of Humira from Swiss drugmaker Novartis' […]
Geisinger Program Slows Spending Growth on Biologics
A comparative effectiveness program launched by Geisinger Health has reportedly slowed the rapid increase in biologic spending, according to an HFMA report. According to the report, Geisinger Health Plan's spending on biologics accounted for about 35.9 percent of its total drug spending in 2018, […]
2015 Comparative Effectiveness Research Infographic
Now in its fifth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Infographic available for download here. (Source: National Pharmaceutical […]
The Myth of Average: Infographic for Patients
Understanding which health care treatments or preventive care will work best for you is important. This infographic for patients is available for download here. (Source: National Pharmaceutical Council) […]
The Myth of Average (Health Professionals) Infographic
Understanding which health care treatments or preventative care will work best for you is important. Infographic available for download here. (Source: National Pharmaceutical Council) […]
2014 Comparative Effectiveness Research and the Environment for Health Care Decision-Making Infographic
Now in its fourth year, the National Pharmaceutical Council's annual survey of health care stakeholders continues to shed light on the environment for comparative effectiveness research (CER) and health care decision-making. Take a look at this infographic. (Source: National Pharmaceutical Council) […]
National Pharmaceutical Council. 2014 Comparative Effectiveness Research and Environment Health Care Decision-Making Infographic.
Or download the infographic PDF file here. […]
Health Care Decision Makers’ Use of Comparative Effectiveness Research: Report from a Series of Focus Groups
Challenging a Sacred Cow: The Top-Down Approach to Comparative Effectiveness
Blog posting by Nick Emptage, healthycriticism.com, describing CER goals, considerations (statistical sig, measured effect meaning, whether comparisons are valid). […]
Demystifying Comparative Effectiveness Research: A Case Study Learning Guide
Infographic: Is Comparative Effectiveness Research Meeting Market Demand?
Since January 2010, HTA organizations across the globe have issued nearly 1,000 CE reports. Yet just 5% of this U.S.-based research and 9% of research outside the U.S. address four high-burden conditions: non-small cell lung cancer, rheumatoid arthritis, multiple sclerosis and hepatitis C. […]
Methods in Comparative Effectiveness Research
Communicating About Comparative Effectiveness Research: A Health Affairs Symposium on the Issues
Opportunities and Challenges for Comparative Effectiveness Pragmatic Clinical Trials in Europe, PPT
Presentation at ISPOR Europe, Nov. 2011, by Marc L. Berger, M.D., Executive Vice President & Senior Scientist, Life Sciences, OptumInsight, New York, NY, USA […]
Personalized Medicine and Companion Diagnostics in Oncology: Challenges and Solutions, PPT
Presentation at ISPOR Europe, Nov. 2011, by Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK […]
FDAMA Section 114 and CER Master Slide Deck
Master slide deck from Tufts University which covers FDAMA Section 114 and CER […]
Role of Government in CER
Presentation from Clifford Goodman, PhD delivered at the National Comparative Effectiveness Summit, Oct. 13, 2011 […]
Using Comparative Effectiveness Research to Inform Policymaking
Policymakers often use the research these organizations generate to determine the content of publicly provided health benefits […]
Videos: JAMA Theme Issue on Comparative Effectiveness Research
Welcome and Opening Remarks: Phil B. Fontanarosa, M.D., M.B.A., Executive Editor, JAMA […]
